This board had a grand total of 7 posts since the company's IPO of nearly 2 years ago. Success breeds bandwagon enthusiasm. Of course, I knew it was coming and said so long before it did.
Did you know that Trevena was born less than 10 years ago, went public less than 2 years ago, and yet has 4 blockbuster drug candidates - 2 in late-stage development?
Did you know that Trevena's GPCR Biased Ligand technology platform is a Nobel Award winning twist on the G-Protein Coupled Receptor technology platform responsible for over 40% of the approved drug products in the world today?
Did you know that TRV130 at one-tenth and one-third the dosage of morphine in the latest clinical trial proved to be more effective in the first 2 crucial hours of pain reduction, as effective over 24 hours, with markedly fewer incidences of respiratory depression (the major cause of death while using morphine) and fewer incidences of nausea and vomiting?
Think about it!
Sentiment: Strong Buy
That's probably because KIRO was doing everything they could to get rid of him...but couldn't. Not only was he driving advertising dollars away - local companies hated the anti-Christian zeal, but he was becoming a magnet for hate-crime perps. Me? I loved how he tormented bigots. But that's just me.
No, but I wouldn't be ashamed were that to be the case. He was highly entertaining. Did you live that close on the awful day of his demise?
Omidra doesn't address a blockbuster market like TRV130 does. Omeros pipeline is nonexistent. Trevena's pipe is loaded with gold and gilded partnerships. Good luck!
Sentiment: Strong Buy
I'm looking for a major announcement on a debt facility of some kind. Should that occur, the stock could quickly triple from today's level.
Looks like mr market changed his mind.
ronsmithson54 comes with a black box warning: read posts - get brain damage.
Where do you get your 96.4% IO figure? NASDAQ has 62.74% Please source.
That's because they've previously made clear their intent to pursue that indication first.
nitabosco, you write: "The CEO and CMO of the company receive 3.5% and 1.3% of the enterprise value of a buyout..."
I know you're right about this but can you source this for me please?
The appointment of Yacoub Habib Ph.D. to lead the company's partnering and licensing initiatives is interesting in that it indicates Trevena's willingness to look at further partnering beyond 027 that might include its pain portfolio while simultaneously retaining the migraine asset.
Nimble and smart.
cherryhilljoe, being "above a buck" is a NASDAQ requirement and isn't the issue for the NYSE or NovaBay. The issue has to do with operating capital requirements. Those aren't as easily fixed but are another set of issues altogether.